RGNX
REGENXBIO Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.03
−2.25%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$1.21
- Revenue estimate
- $15.9M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- $0.43
- EPS estimate
- $0.08
- Revenue actual
- $108.0M
- Revenue estimate
- $97.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +101.0%
- Revenue beats (12Q)
- 1
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $20
- PT range
- $12 – $29
- Analysts
- 4
3 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | $0.08 | $0.43 | Beat 446.17% | $108.0M |
| May 14, 2026 | -$1.36 | -$1.72 | Miss -26.47% | $6.4M |
| Mar 5, 2026 | -$1.01 | -$1.30 | Miss -28.71% | $30.3M |
| Nov 6, 2025 | -$1.38 | -$1.20 | Beat 13.04% | $29.7M |
| Aug 7, 2025 | -$1.13 | -$1.38 | Miss -22.12% | $21.4M |
| Mar 13, 2025 | -$1.27 | -$1.01 | Beat 20.47% | $21.2M |
| Aug 1, 2024 | -$1.29 | -$1.05 | Beat 18.60% | $22.3M |
| Feb 27, 2024 | -$1.27 | -$1.43 | Miss -12.60% | $22.2M |
| Aug 2, 2023 | -$1.26 | -$1.66 | Miss -31.75% | $20.0M |
| May 3, 2023 | -$1.52 | -$1.53 | Miss -0.66% | $19.1M |
| Feb 28, 2023 | -$1.48 | -$1.38 | Beat 6.76% | $31.3M |
| Nov 3, 2022 | -$1.55 | -$1.75 | Miss -12.90% | $26.5M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026